Why AMD Stock Is Jumping Today
AMD stock is rising today following news that bans on key technology exports to China have been lifted.
Being able to sell its artificial intelligence (AI) processors in the Chinese market is a significant positive development for AMD.
An investment firm raised its one-year price target on AMD from $175 per share to $200 per share.
10 stocks we like better than Advanced Micro Devices ›
Advanced Micro Devices (NASDAQ: AMD) stock is gaining ground again Tuesday. The company's share price was up 2.6% as of 12:30 p.m. ET. Meanwhile, the S&P 500 (SNPINDEX: ^GSPC) was down 0.2%, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) was down 0.3%. The stock had been up as much as 5% earlier in trading.
AMD's stock is rising today thanks to news that the Trump administration is suspending restrictions that prevented advanced semiconductors and other technologies from being exported to China. The semiconductor stock is also getting a lift from bullish analyst coverage.
AMD stock rises on China news
The Trump administration has at least temporarily lifted export bans that prevented AMD from selling its high-end artificial intelligence (AI) processors into the Chinese market. The move is a concession as Trump aims to secure a trade deal with China, and it could wind up being a significant positive sales and earnings catalyst for AMD. While increased potential for a trade deal to be reached between the two countries is a beneficial development for AMD, the significance that the AI race holds for both countries along national security and economic lines suggests that substantial geopolitical risk factors are still on the table.
Is AMD stock headed to $200?
Before the market opened this morning, Bank of America published new coverage on AMD and raised its one-year price target on the stock from $175 per share to $200 per share. BofA's analysts think that the chipmaker's share of the central processing unit (CPU) market could rise from 20% in 2023 to 30% next year.
In addition to taking market share from Intel in the CPU space, Bank of America's analysts noted that AMD's processors are commanding a 17% pricing premium compared to offerings from its competitor. While AMD's performance in the CPU space will continue to be a key factor in the company's performance, sales results for its graphics processing units (GPUs) for AI data centers will likely be the biggest factor shaping the stock's next moves when the company reports its Q2 results on Aug. 5.
Should you invest $1,000 in Advanced Micro Devices right now?
Before you buy stock in Advanced Micro Devices, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Advanced Micro Devices wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $633,452!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,083,392!*
Now, it's worth noting Stock Advisor's total average return is 1,046% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 29, 2025
Bank of America is an advertising partner of Motley Fool Money. Keith Noonan has positions in Intel. The Motley Fool has positions in and recommends Advanced Micro Devices and Intel. The Motley Fool recommends the following options: short August 2025 $24 calls on Intel. The Motley Fool has a disclosure policy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
24 minutes ago
- CBC
Gaza's hunger crisis + Duty-free fears
The National takes a closer look at the rapidly deteriorating hunger crisis in Gaza and the significance of Canada's plan to recognize a Palestinian state. And family-run duty-free shops fear Trump's trade war will put them out of business.
Globe and Mail
26 minutes ago
- Globe and Mail
Wave (WVE) Q2 Revenue Drops 56%
Key Points Revenue declined sharply to $8.7 million in Q2 fiscal year 2025, missing analyst expectations by 34.1% and falling 55.8% compared to the prior year period. Net loss widened to $50.5 million for Q2 2025, as research and administrative costs increased and Revenue fell to $8.7 million in Q2 2025 from $19.7 million in Q2 2024. Pipeline progress remained robust. These 10 stocks could mint the next wave of millionaires › Wave Life Sciences (NASDAQ:WVE), a clinical-stage biotechnology company focused on RNA-based medicines, reported second-quarter earnings on July 30, 2025, for the period ending June 30. The company missed Wall Street expectations by a wide margin, delivering revenue of $8.7 million for Q2 2025 versus analyst forecasts of $13.2 million and an earnings per share (EPS) loss of $0.31 for Q2 2025, compared to the anticipated loss of $0.28. Revenue fell 55.8% in the second quarter of 2025 compared to the prior year period. Operating expenses rose compared to the same period in 2024 as well, with research and administrative spending increased year over year in Q2 2025, contributing to a higher net loss for the second quarter of 2025 compared to the prior year period. Despite these financial setbacks, the company reported continued pipeline and clinical progress, but the absence of new partnership income and the accelerated cash burn put the focus firmly on near-term trial results and strategy execution. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.31) $(0.28) $(0.25) (24.0%) Revenue (GAAP) $8.7 million $13.2 million $19.7 million (55.8%) Research and Development Expense $43.5 million $40.4 million 7.7% General and Administrative Expense $18.0 million $14.3 million 25.9% Net Loss $(50.5 million) $(32.9 million) (53.5%) Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Company Overview and Strategic Focus Wave Life Sciences is dedicated to developing RNA-based medicines using its proprietary PRISM platform. This technology enables the company to design stereopure oligonucleotides -- specialized, chemically controlled strands of nucleic acids -- allowing greater control over drug properties like efficacy and safety. By leveraging this approach, it aims to create therapies for a wide range of genetic disorders, from rare conditions to broader public health challenges. Recently, Wave Life Sciences has built a diverse portfolio, with candidates in clinical testing for obesity, alpha-1 antitrypsin deficiency (AATD), Duchenne muscular dystrophy (DMD), and Huntington's disease (HD). Success hinges on the advancement of these programs, the validation and expansion of the PRISM platform, and the ability to secure partnerships or licensing deals that can both fund ongoing research and commercialize discoveries. Key Developments in the Quarter The quarter's most immediate headline was the steep drop in revenue, which nearly halved compared to the same period in 2024. No new partnership agreements or large milestone payments offset this gap. At the same time, the company continued to increase research and development spending, which rose approximately 7.7% in the second quarter of 2025 compared to the same period in 2024. General and administrative costs, covering business operations and staff, increased by 25.9% in Q2 2025 compared to Q2 2024, resulting in a net loss of $50.5 million, 53.5% greater than the loss reported in the prior year period. Pipeline progress remained a crucial theme. Wave's PRISM technology continued to support the development of new assets and clinical advances. In AATD, the WVE-006 oligonucleotide program advanced as the company completed multidosing in a 200mg cohort and started single dosing at 400mg. According to management, *RestorAATion-2 clinical data from the complete 200 mg single and multidose cohorts remain on track for Q3 2025; data from the complete 400 mg single dose cohort remain on track for fall 2025.* In obesity, the INLIGHT clinical trial for WVE-007—a GalNAc-conjugated small interfering RNA (siRNA) targeting INHBE mRNA—expanded its second cohort from eight to 32 participants in Q2 2025, based on promising safety and biomarker data. Preclinical data for WVE-007 presented in June 2025 demonstrated efficacy comparable to semaglutide in terms of fat loss, with potential for dosing only once or twice a year. In DMD, the exon-skipping oligonucleotide WVE-N531 produced encouraging results in a 48-week Phase 2 trial, reporting a statistically significant improvement in Time-to-Rise (a measure of muscle function) as well as reduced muscle damage markers. Wave confirmed that its New Drug Application (NDA) filing for WVE-N531 is planned for 2026, citing positive engagement with the U.S. Food and Drug Administration (FDA). For Huntington's disease, the company continues to develop WVE-003, an allele-selective oligonucleotide. Preparation is ongoing for a potentially registrational, global Phase 2/3 study of WVE-003 in adults with SNP3 and Huntington's disease. Strategic partnerships were not a revenue or milestone driver this quarter. Although its collaboration with GSK could result in future milestone payments of up to $3.3 billion, these are not yet factored into its immediate forecasts or cash runway. The company's cash and cash equivalents fell from $302.1 million at December 31, 2024, to $208.5 million at June 30, 2025. Deferred revenue also dropped. Wave also appointed Dr. Christopher Wright as its new Chief Medical Officer to strengthen its clinical and regulatory operations. Looking Ahead The company maintained that it expects to fund its operations into 2027 with current cash resources. However, this forecast does not include possible milestone payments from the GSK partnership and is sensitive to the rate of future cash spending. Continued expense growth or delays in securing new partnerships could affect the duration of its financial runway. Wave Life Sciences did not provide explicit revenue or earnings guidance for upcoming periods. Investors are expected to focus on upcoming clinical readouts, including data from the AATD RestorAATion-2 200mg cohort in the third quarter, INLIGHT obesity trial results later in the year, and the start of pivotal clinical trials in Huntington's disease. Delays or adverse outcomes in these trials, or the absence of new collaboration agreements, could have a significant impact on future financial performance and funding ability. WVE does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,039%* — a market-crushing outperformance compared to 182% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of July 29, 2025
Canada News.Net
an hour ago
- Canada News.Net
CK Hutchison revises ports deal plan amid Beijing scrutiny
HONG KONG: CK Hutchison is exploring the inclusion of a major Chinese investor in the proposed US$22.8 billion sale of its global ports business, following regulatory scrutiny from Beijing that has complicated progress on the deal. The move comes after the Hong Kong-based conglomerate concluded exclusive talks with a consortium led by U.S. investment giant BlackRock and Italy's MSC, the shipping group controlled by billionaire Gianluigi Aponte. The initial agreement, reached in March, covered 43 port assets across 23 countries, including two key terminals located along the Panama Canal, a region of strategic interest to both China and the United States. With the exclusivity window closed, CK Hutchison said changes in both the consortium's structure and the transaction itself are now likely to be required to secure the necessary regulatory approvals. The company emphasized it would not proceed without clearance from all relevant authorities and said it is open to taking additional time to ensure compliance. In a filing to the Hong Kong Stock Exchange on July 28, the company confirmed it is in discussions with the existing consortium to bring in a "major strategic" Chinese investor. A source familiar with the matter told Reuters that China COSCO Shipping Corp, one of the country's largest port operators, is in talks to join the group. While BlackRock declined to comment, neither MSC nor COSCO responded to requests for comment. CK Hutchison also refused to provide further details beyond its official exchange filing. The development comes amid increased geopolitical friction, particularly following remarks by U.S. President Donald Trump, who previously called for U.S. control of the Panama Canal and praised the port sale as a symbolic "reclaiming" of the region. His administration had also raised concerns over Chinese control of port assets near the canal. China's State Administration for Market Regulation has announced it will review the deal under antitrust laws to ensure market fairness and protect the public interest. While the regulator did not provide additional comments, state-run Chinese media criticized the proposed transaction, warning that it undermines national interests. In its latest statement, CK Hutchison said that any new investor joining the consortium must be a significant participant in the group. Analysts remain cautious about how the situation will evolve. David Blennerhassett, strategist at Ballingal Investment Advisors, noted that the majority Chinese control of the consortium would likely face resistance. However, a minority stake may ease geopolitical tensions while maintaining deal viability. JPMorgan analysts echoed that view, stating in a client note that adding COSCO could address some of Beijing's concerns and improve the chances of approval. They also flagged that some port assets—especially those in Panama—may be excluded from the final agreement, which could affect both the structure and pricing of the revised deal. CK Hutchison's shares rose 1.6 percent on July 28, outperforming the broader Hang Seng Index, which gained 0.9 percent.
